Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun;37(6):1499-508.
doi: 10.2337/dc13-2743.

Insulin therapy in people with type 2 diabetes: opportunities and challenges?

Affiliations

Insulin therapy in people with type 2 diabetes: opportunities and challenges?

Philip Home et al. Diabetes Care. 2014 Jun.

Abstract

Given the continued interest in defining the optimal management of individuals with type 2 diabetes, the Editor of Diabetes Care convened a working party of diabetes specialists to examine this topic in the context of insulin therapy. This was prompted by recent new evidence on the use of insulin in such people. The group was aware of evidence that the benefits of insulin therapy are still usually offered late, and thus the aim of the discussion was how to define the optimal timing and basis for decisions regarding insulin and to apply these concepts in practice. It was noted that recent evidence had built upon that of the previous decades, together confirming the benefits and safety of insulin therapy, albeit with concerns about the potential for hypoglycemia and gain in body weight. Insulin offers a unique ability to control hyperglycemia, being used from the time of diagnosis in some circumstances, when metabolic control is disturbed by medical illness, procedures, or therapy, as well as in the longer term in ambulatory care. For those previously starting insulin, various other forms of therapy can be added later, which offer complementary effects appropriate to individual needs. Here we review current evidence and circumstances in which insulin can be used, consider individualized choices of alternatives and combination regimens, and offer some guidance on personalized targets and tactics for glycemic control in type 2 diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of the use of insulin and other glucose-lowering approaches over the course of time in a person with type 2 diabetes. ause of insulin may be temporary. BP, blood pressure; OGLDs, oral glucose-lowering drugs; TG, triglyceride.

Comment in

References

    1. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535–1540 - PubMed
    1. Shah BR, Hux JE, Laupacis A, Mdcm BZ, Austin PC, van Walraven C. Diabetic patients with prior specialist care have better glycaemic control than those with prior primary care. J Eval Clin Pract 2005;11:568–575 - PubMed
    1. Home P, Naggar NE, Khamseh M, et al. . An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study. Diabetes Res Clin Pract 2011;94:352–363 - PubMed
    1. Peyrot M, Rubin RR, Lauritzen T, et al. International DAWN Advisory Panel . Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673–2679 - PubMed
    1. U.K. Prospective Diabetes Study Group . U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249–1258 - PubMed

MeSH terms